High Efficiency Cell Engineering Workshop at NIH

The benefits of non-viral, scalable transfection for assay development, protein production and cell therapy enablement

Date: Tuesday Sept 24, 2024
Time: 10:00-11:00 AM

In-person

NIH
Building 10 FAES Classrooms
Room 7
Bethesda, MD

About the workshop

Engineering cells to develop biological assays, produce recombinant proteins or create cellular therapies requires highly efficient, scalable and reproducible methods for transfecting nucleic acids, proteins and other macromolecules. However, cell line development is a lengthy process that becomes even more challenging when working with complex assays, difficult to express products, or expensive and time-consuming viral methods. Moreover, stable cell lines are rarely suitable for cell and gene therapy applications. In this presentation, we’ll discuss the benefits of transient transfection at overcoming the limitations of engineered, stable cell lines and viral-based workflows. In particular, we’ll focus on the advantages of scalable electroporation for efficiently engineering primary cells, stem cells and other cell types for all phases of therapeutic development, from basic research to cGMP manufacturing. Data will be shared on CRISPR-based gene editing, assay development for membrane protein screening, and rapid production of antibodies in CHO cells.

Headshot of Megan Embrey

Megan Embrey, MS

Field Application Scientist
MaxCyte, Inc.

Megan is based in Bethesda Maryland, working alongside MaxCyte’s portfolio of protein production and cell therapy clients. Professionally, Megan has worked as a cell biologist at the University of Virginia and earned an MS. in microbiology from the University of Maine. Outside of work, Megan helps lead a Women in Biology - Peer Mentorship program, enjoys hiking, and is always looking for a new recipe to try.

Caroline Romanelli

Caroline Romanelli

Business Development Manager
MaxCyte, Inc.

After earning her MS. Biochemistry from the University of Delaware, Caroline spent 10 years at Bristol-Myers Squibb in Leads Discovery and Optimization, focusing on label-free assay development, lab automation, and fragment screening. Since leaving the bench, Caroline has enjoyed providing innovative solutions in today’s fast-paced life science industry, when not with her daughters, at the beach, or watching Philadelphia sports.

 

RSVP

Fill out the form below to attend the in-person seminar